2010 'a watershed year' for lung cancer

Today, Lung Cancer Alliance (LCA) called 2010 "a watershed year" for lung cancer that included increased research funding, additional Congressional support, a new national coalition of key policy organizations, and the validation of CT screening  - a convergence of forces that can reverse the historic underfunding and neglect of lung cancer.

LCA President and CEO Laurie Fenton Ambrose said, "This is the most important year to date and looking back years from now 2010 will be seen as the turning point."

"We are building a solid coalition of support within Congress and within the top public health, medical and social justice organizations in the country," she said.

Even as Congress wraps up its work this week, support continued to grow in the lame duck session with the addition of Senator Jim Webb (D-VA), Congressman Ben Chandler (D-KY) and Congressman Geoff Davis (R-KY) as co-sponsors of the Lung Cancer Mortality Reduction Act - a bicameral and bi-partisan bill that authorizes the first comprehensive research program specifically for lung cancer.

To date, 61 members of the House of Representatives and 22 Senators have signed on.

Meanwhile, the Native Indian Health Board has recently joined the growing list of over 40 highly respected institutes and organizations calling for a more compassionate and comprehensive plan to address all aspects of lung cancer.  

Earlier this year, Congress appropriated an additional $15 million for the lung cancer research program which was launched with $20 million in fiscal year 2009 through the Department of Defense's Congressionally Directed Medical Research program. Additional funding for fiscal year 2011 has made it through Committee but Congress will not complete action on the new budget until March.

"Additionally, as we continued to build support within Congress and grow our national network, the announcement by Dr. Harold Varmus, the Director of the National Cancer Institute about the results of the National Lung Cancer Screening Trial (NLST) marked a critical turning point in the history of the disease and will accelerate our call to action," Fenton Ambrose said. 

The eight year old NLST of 50,000 people at high risk for lung cancer was suspended before its anticipated completion because of the strength of the evidence that CT scans can detect lung cancer at early stage and reduce mortality.

"We end 2010 on a high note and well positioned to engage the 112th Congress," concluded Fenton Ambrose.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI models redefine TIL scoring in breast cancer but face challenges in real-world validation